Drug Topics
SEPTEMBER 1, 2024
In case you missed it, this week we had news about COVID-19 and the upcoming respiratory virus season, advancements in clinical trials for ASCVD, the first OTC birth control, and more.
STAT
SEPTEMBER 1, 2024
HCA Healthcare and UnitedHealthcare reached agreements just hours before their contracts were scheduled to expire on Sunday, capping a monthslong dispute that threatened in-network access to 38 hospitals across four states. The country’s biggest hospital chain and its biggest insurer had been duking it out for months to no avail before they finalized terms on Saturday evening.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
SEPTEMBER 1, 2024
The exhaled breath condensate mask was able to successfully monitor and accurately detect breath for nitrate in patients with asthma or chronic obstructive pulmonary disease.
STAT
SEPTEMBER 1, 2024
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a phase 3 study, potentially clearing the way for regulatory approval, although in two other studies, patients earlier in the disease failed to see a benefit. A top company executive said he believes that the positive result would help build confidence among investors in the company’s research and development efforts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
SEPTEMBER 1, 2024
Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to have disappointed investors.Shares in the company retreated after the presentation of the results at the European Society of Cardiology (ESC) conference, which confirmed a 28% reduction in the primary endpoint of deaths from any cause and recurrent cardiovascular events after at least 33 months of follow-up.
Fierce Pharma
SEPTEMBER 1, 2024
With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). | At the European Society of Cardiology (ESC) event, Bayer unveiled data from the 3 FINEARTS-HF trial that showed Kerendia reduced the risk of cardiovascular death, as well as well as first and recurrent HF events by 16% compared to placebo in patients with mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Med Ed 101
SEPTEMBER 1, 2024
A 76-year-old male has a past medical history of hypertension, diarrhea, mild cognitive impairment, diabetes, osteoarthritis, and gout. He has had a concern that has been ongoing for about 3 months with the symptoms recently escalating over the last 1-2 weeks. “Diarrhea problems” is what the patient is reporting. His primary provider recently did a […] The post Diarrhea Problems – Case Study appeared first on Med Ed 101.
Oswald's
SEPTEMBER 1, 2024
Promotions at Oswald's Pharmacy running from September 1 - 30, 2024.
Pharmaceutical Technology
SEPTEMBER 1, 2024
A large proportion of chronic heart failure (HF) patients are taking suboptimal doses of relevant medications.
STAT
SEPTEMBER 1, 2024
Robert F. Kennedy Jr.’s priorities may seem like a random grab bag of contrarianism, conspiracies, and earnest environmental activism: vaccine skepticism , Bitcoin enthusiasm , government-run organic farming communes to wean people off pharmaceuticals , opposition to corporate polluters , embrace of climate change skeptics. But there is nothing random about these positions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Expert insights. Personalized for you.
190 
Let's personalize your content